Viridian Therapeutics Inc
VRDNHealthcare|Biotechnology|USA
$19.75
-0.46 (-2.28%)
Tangible Book
$4.92
About
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Stock Price
+15.3%(1Y)
Pipeline Summary
8 total trials0
Phase 1
0
Phase 2
8
Phase 3
0
Phase 4
Completed: 5Active: 3
Active Trials (3)
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
NCT06812325Thyroid Eye Disease (TED)
Phase 3Active
Enrollment: 320 participants
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
NCT06625411Thyroid Eye Disease
Phase 3Active
Enrollment: 132 participants
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
NCT06625398Thyroid Eye Disease
Phase 3Active
Enrollment: 204 participants
BioScore
6.7/10
Buy
Ownership
Recent Insider Trades
Fairmount Healthcare Fund II GP LLCBUY
2026-05-111,176,470 shares @ $17
Tousignant JenniferSELL
2025-12-312,272 shares @ $31.16
Fairmount Healthcare Fund II GP LLCBUY
2025-10-23454,545 shares @ $22
Beetham Thomas W.BUY
2024-09-275,000 shares @ $23.41
Mahoney Stephen F.BUY
2024-09-2721,400 shares @ $23.33
Recent News
2026-06-30 16:04:24
2026-06-30 14:35:51
2026-06-30 13:32:54
2026-06-30 10:30:27
2026-06-29 17:33:58
Data last updated: Jul 12, 2026, 07:38 PM